Everhart Financial Group Inc. Acquires New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Everhart Financial Group Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,592 shares of the biopharmaceutical company’s stock, valued at approximately $239,000.

Several other institutional investors also recently modified their holdings of GILD. AMF Tjanstepension AB raised its position in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock worth $33,645,000 after acquiring an additional 51,390 shares in the last quarter. Creative Planning boosted its holdings in shares of Gilead Sciences by 16.1% during the 3rd quarter. Creative Planning now owns 219,045 shares of the biopharmaceutical company’s stock worth $18,365,000 after buying an additional 30,451 shares in the last quarter. Swedbank AB grew its position in shares of Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after buying an additional 189,622 shares during the period. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at $25,000. Finally, Global Retirement Partners LLC boosted its stake in Gilead Sciences by 11.9% during the third quarter. Global Retirement Partners LLC now owns 8,788 shares of the biopharmaceutical company’s stock worth $737,000 after acquiring an additional 933 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GILD shares. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Citigroup initiated coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Oppenheimer lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Finally, Royal Bank of Canada upped their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.33.

Gilead Sciences Stock Performance

Shares of GILD opened at $104.08 on Tuesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a 50-day moving average of $93.87 and a two-hundred day moving average of $87.70. The stock has a market cap of $129.71 billion, a P/E ratio of 1,156.44, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $106.69.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. As a group, research analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.04%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 137,676 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the transaction, the chief financial officer now owns 171,223 shares in the company, valued at approximately $17,502,415.06. This trade represents a 44.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 710,500 shares of company stock valued at $67,684,956 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.